Gliflozinas. Inhibidores
Gliflozinas. Inhibidores del cotransporte sodio-glucosa Tipo 2 // Ezequiel J Zaidel9. Ministerio de Salud Pública. Anuario de estadísticas de salud 2019. Disponible en: https://www.salud.gob.ec/wp-content/uploads/2020/07/ANUARIO-DE-ESTADISTICAS-DE-SALUD-2019.pdf. Accedido el 10 de Marzo de 2023.10. Ministerio de Salud de la Nación. Encuesta Nacional de Factores de Riesgo 2018. Disponible en: https://www.argentina.gob.ar/sites/default/files/encuesta-nacional-factores-riesgo-2018.pdf. Accedido el 10 de Marzo de 2023.11. International Diabetes Federation. IDF Diabetes Atlas, Ninth edition 2019. Disponible en: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf. Accedido el 10 de Marzo de 2023.12. Bernabe-Ortiz A, Carrillo-Larco RM. The burden of diabetes in the Americas. Lancet Diabetes Endocrinol.2022 Sep;10(9):613-614. doi: 10.1016/S2213-8587(22)00196-6. Epub 2022 Jul 15. PMID: 35850130.13. Mosenzon O, Alguwaihes A, Leon JLA, et al. CAPTURE: a multinational, cross-sectional study of cardiovasculardisease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154.Published 2021 Jul 27. doi:10.1186/s12933-021-01344-0.14. Dieuzeide G, Waitman J, Pugnaloni Rodríguez NS, et al. CAPTURE Study: Argentine results on prevalenceof cardiovascular disease in type 2 diabetes mellitus. Medicina (B Aires). 2022;82(3):398-407.15. Swinburn BA, Kraak VI, Allender S, et al. The Global Syndemic of Obesity, Undernutrition, and Climate Change:The Lancet Commission report. Lancet. 2019;393(10173):791-846. doi:10.1016/S0140-6736(18)32822-8.16. FAO, OPS, WFP y UNICEF. 2019. Panorama de la seguridad alimentaria y nutrición en América Latina y elCaribe 2019. Santiago. 136. https://iris.paho.org/handle/10665.2/51685.17. Centers for Disease Control and Prevention. (2020). Adult Obesity Facts. Recuperado de https://www.cdc.gov/obesity/data/adult.html.18. Ministerio de Salud de la Nación. (2019). Encuesta Nacional de Factores de Riesgo 2018. Recuperado dehttps://www.argentina.gob.ar/sites/default/files/2019_encuesta_nacional_de_factores_de_riesgo.pdf.19. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesityin 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27. doi:10.1056/NEJMoa1614362 .20. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease [published correction appears in Circ Res.2015 Jun 19;117(1):e12]. Circ Res. 2015;116(9):1509-1526. doi:10.1161/CIRCRESAHA.116.303849 .21. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheralartery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-1340.doi:10.1016/S0140-6736(13)61249-0.22. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report Fromthe American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.23. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11.doi:10.15420/cfr.2016:25:2.24. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the Impact of Heart Failure in the United States:A Policy Statement From the American Heart Association. Circ Heart Fail. 2013;6(3):606-619. doi:10.1161/HHF.0b013e318291329a).25. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific Treatment of Heart Failure With PreservedEjection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90. doi:10.1161/CIRCULATIONA-HA.116.021884.26. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reducedejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770-1780.doi:10.1093/eurheartj/ehy005.27. Tromp J, Teng TH, Tay WT, et al. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail.2019;21(1):23-36. doi:10.1002/ejhf.1227.28. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation inthe European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-2751. doi:10.1093/eurheartj/eht280.29. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County,Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125.30. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burdenof Disease 2010 Study. Circulation. 2014;129:837–847.31. Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from sevencountries in Latin America. Int J Gen Med. 2014;7:441-448. Published 2014 Sep 2. doi:10.2147/IJGM.S62819.32. Lip GY, Kakar P, Watson T. Atrial fibrillation--the growing epidemic. Heart. 2007;93(5):542-543.doi:10.1136/hrt.2006.110791.33. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and17
Gliflozinas. Inhibidores del cotransporte sodio-glucosa Tipo 2 // Ezequiel J ZaidelMeta-Analysis. PLoS One. 2016;11(7):e0158765. Published 2016 Jul 6. doi:10.1371/journal.pone.0158765.34. National Kidney Foundation. Kidney Disease Statistics for the United States. https://www.kidney.org/news/newsroom/factsheets/KidneyDiseaseBasics. Accessed March 30, 2022.35. Kramer A, Boenink R, Stel VS, et al. The ERA-EDTA Registry Annual Report 2018: a summary. Clin KidneyJ. 2020;14(1):107-123. Published 2020 Dec 24. doi:10.1093/ckj/sfaa271.36. Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. SeminNephrol. 2013;33(5):468-475. doi:10.1016/j.semnephrol.2013.07.008.37. Garcia-Garcia G, Jha V. CKD in disadvantaged populations. J Nephrol. 2015;28(1):1-5. doi:10.1007/s40620-015-0172-6.38. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fattyliver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.doi:10.1002/hep.28431.39. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitisamong a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology.2011;140(1):124-131. doi:10.1053/j.gastro.2010.09.038.40. Rinella ME, Sanyal AJ. NAFLD in2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015;12(2):65-66. doi:10.1038/nrgastro.2014.232.18
